Aviragen Therapeutics Inc (AVIR) Could Start To Move Near Term

It seems only recently that the company wrapped up the completion of Phase 2a clinical trials for its respiratory syncytial virus (RSV) drug BTA585, but Aviragen Therapeutics ...

Keep Reading →